Bryan Johnson reconsiders anti‑aging pursuits after autoimmune diagnosis

American entrepreneur and biohacker Bryan Johnson, who invests roughly US$2 million a year in protocols aimed at slowing biological aging, announced that a recent diagnosis of an autoimmune disease has led him to question the limits of his longevity experiments. Johnson, known for publicly sharing his rigorous health regimen, said he is now reflecting on whether he has pushed beyond safe boundaries in his quest to reduce his biological age.

Johnson also disclosed a separate project in which he reprogrammed his own adult cells into induced pluripotent stem cells, creating a line he calls “Baby Bryan.” The cell line is used to generate organoids for research on disease and drug testing, and is not a cloned human or a source of transplantable organs. While the work illustrates the experimental frontier of regenerative medicine, experts note that fully functional organ production remains far from clinical reality. Johnson’s statements have reignited debate over the ethical and medical boundaries of anti‑aging research.